Now approved: Pulmozyme with the PARI eRapid™ Nebulizer System

Since its approval in 1993, Pulmozyme has been a cornerstone of cystic fibrosis (CF) therapy. We would like to announce that Pulmozyme has been approved for use with the eRapid Nebulizer System, which delivers short treatment times.*

What is the eRapid Nebulizer System?
- The eRapid Nebulizer System is a general-purpose electronic nebulizer that is able to deliver aerosolized medications
- A phase IV study was done to evaluate comparable efficacy and safety of the PARI eRapid Nebulizer System, which is now a part of the approved list of nebulizers that deliver Pulmozyme treatments
- The eRapid Nebulizer System is small, portable, quiet, and quick**

Approved nebulizers and compressors

<table>
<thead>
<tr>
<th>Jet Nebulizers</th>
<th>Compressors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hudson T Up-draft II® with</td>
<td>Pulmo-Aide®</td>
</tr>
<tr>
<td>Marquest Acorn II® with</td>
<td>Pulmo-Aide®</td>
</tr>
<tr>
<td>PARI LC® Plus with</td>
<td>PARI PRONEB®</td>
</tr>
<tr>
<td>‘PARI BABY’™ with</td>
<td>PARI PRONEB®</td>
</tr>
<tr>
<td>Durable Sidestream® with</td>
<td>MOBILAIRE™</td>
</tr>
<tr>
<td>Durable Sidestream® with</td>
<td>Porta-Neb®</td>
</tr>
</tbody>
</table>

Nebulizer System

PARI eRapid™ Nebulizer System†

Coverage and reimbursement
- Gaining access to the eRapid Nebulizer System may involve reimbursement challenges and the eRapid Nebulizer System may not be approved by many payers.
- Patients who have coverage may encounter significant out-of-pocket costs and patients who do not have coverage may expect to pay full retail price
- For more information on the eRapid Nebulizer System, call PARI at (866) 335-6943 or visit www.pari.com
- For more information on Pulmozyme, talk to your local Genentech representative

*The average nebulization time for the eRapid Nebulizer System is approximately 2-3 minutes compared to the LC® Plus Jet Nebulizer, which is 6-10 minutes.†

INDICATION
Pulmozyme (dornase alfa) is indicated for daily administration in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.

IMPORTANT SAFETY INFORMATION
- Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product
- The most common adverse reactions associated with the use of Pulmozyme include: voice alteration, pharyngitis, rash, laryngitis, chest pain, conjunctivitis, rhinitis, decrease in FVC of ≥ 10%, fever, dyspepsia, and dyspnea. There have been no reports of anaphylaxis attributed to the administration of Pulmozyme. Mild to moderate urticaria and mild skin rash have been observed and have been transient

Pulmozyme is a trademark of PARI Pharma GmbH. PARI LC PLUS and PRONEB are registered trademarks and PARI BABY is a trademark of PARI Respiratory Equipment, Inc. Up-draft II is a registered trademark of Teleflex Medical Incorporated Corporation. Acorn and Portaneb are registered trademarks of Medic-Aide Limited. Pulmo-Aide is a registered trademark of DeVilbiss Healthcare LLC. Sidestream is a registered trademark of Respironics (UK) Ltd. MOBILAIRE is a trademark of Invacare Corporation.

Please see accompanying full Pulmozyme Prescribing Information for additional important safety information.